RELIVE
Research type
Research Study
Full title
International registry for paediatric patients with a relapsed or refractory hepatoblastoma or hepatocellular carcinoma
IRAS ID
318128
Contact name
Madhumita Dandapani
Contact email
Sponsor organisation
Geneva University Hospital
Duration of Study in the UK
0 years, 6 months, 30 days
Research summary
Newly diagnosed HB, HCC, or HCN NOS patients are usually treated within the framework of a clinical trial with well-defined treatment options which vary according to the extent of disease and anticipated prognosis of the individual case. Some patients will not be cured with upfront therapy and are considered to have treatment-refractory disease. Other patients may relapse after having been in remission.
There is no standard of care treatment available or open clinical trial in children with relapsed or refractory hepatoblastoma. These children receive 'salvage' treatment which may include chemotherapy or additional surgical and/or interventional approaches aimed towards achieving local control, and treatment is therefore largely individualized according to single institution opinion. Longterm outcome for patients with refractory or relapsed HB, HCC, and HCN-NOS is very poor.
The long- term aim of the international consortium is to incorporate treatment guidelines and data acquisition for relapsed and refractory patients in a prospective fashion as part of a second generation protocol. In order to acheive this, the RELIVE consortium is aiming to retrospectively collect data regarding treatment regimens used in the last two decades as well as short- and long-term patient outcomes. Anecdotal information is insufficient; therefore, we propose to retrospectively collect cases in a central registry allowing for a systematic overview and statistical assessment of the various approaches used.REC name
Yorkshire & The Humber - Leeds West Research Ethics Committee
REC reference
22/YH/0279
Date of REC Opinion
15 Dec 2022
REC opinion
Favourable Opinion